Here is what the page “Moderna-Merck mRNA Cancer Vaccine Shows Promise in Melanoma Trial at ESMO” contains. Moderna and Merck announced early data from a Phase 2b trial of their personalized mRNA cancer vaccine, mRNA-4157 (V940), in combination with Keytruda for high-risk melanoma patients. The results, presented at the European Society for Medical Oncology (ESMO) congress, showed a 44% reduction in the risk of recurrence or death compared to Keytruda alone, and a 65% reduction in the risk of distant metastasis or death. The combination therapy was generally well tolerated, with mostly mild to moderate side effects.
This data is significant because it is among the first to demonstrate clinical benefit of an mRNA cancer vaccine in a randomized trial, potentially paving the way for a new class of personalized cancer immunotherapies. The companies plan to initiate a Phase 3 trial in 2023 and explore the vaccine in other tumor types. The full version stays on the original page, which this listing opens directly.